Top Markets
#1 Islamic Coin Islamic Coin +154.47%
#2 PulseChain PulseChain +49.22%
#3 RedStone RedStone +22.21%
#4 BOOK OF MEME BOOK OF MEME +18.12%
#5 Starpower Starpower +14.19%
#6 Venom Venom +12.35%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.28%
#8 Lighter Lighter +12.26%
#9 Nockchain Nockchain +11.12%
#10 SkyAI SkyAI +10.56%
Coin of the day
Islamic Coin Islamic Coin
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Biocartis Group N.V. Biocartis Group N.V.

Biocartis Group N.V.

BCART
Kedudukan dalam Saham #27531
Biocartis Group NV is a molecular diagnostics firm dedicated to improving... Biocartis Group NV is a molecular diagnostics firm dedicated to improving clinical care. Its innovative diagnostic solutions primarily serve the oncology sector, benefiting patients, medical professionals, insurers, and the broader healthcare ecosystem. The company's cornerstone is its exclusive Idylla molecular diagnostics platform, a sophisticated real-time polymerase chain reaction (PCR) system. This technology delivers crucial molecular data, aiding in the selection of appropriate treatments and the continuous monitoring of patient progress. Biocartis offers a range of diagnostic tests via the Idylla system, including mutation analysis for BRAF, KRAS, MSI, EGFR, and NRAS-BRAF. Additionally, it provides Idylla panels for SARS-CoV-2/Flu/RSV, standalone SARS-CoV-2 tests, and the rapid host-response assessment, SeptiCyte RAPID. For research purposes, the company supplies various mutation assays, such as those for MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R. Biocartis has entered into strategic partnerships to broaden its impact. One such collaboration is with Amgen, focusing on evaluating Idylla RAS testing to enable swift, decentralized diagnostics and enhance the accessibility of RAS biomarker data through the Idylla platform and its associated RAS tests. Another key alliance is with Bristol-Myers Squibb Company, centered on the registration and application of the Idylla MSI test within the field of immuno-oncology treatments. Furthermore, a licensing, development, and commercialization agreement with GeneproDx is in place for the creation of the innovative ThyroidPrint genomic test, to be integrated onto the Idylla platform. Established in 2007, Biocartis maintains its corporate headquarters in Mechelen, Belgium.
Harga Saham
$0.343985
Disegerakkan terakhir: 2024-07-23
Modal Pasaran
$32.31M
Perubahan (1 hari)
11.88%
Perubahan (1 tahun)
0.00%
Negara
BE
Perdagangan Biocartis Group N.V. (BCART)

Kategori

Healthcare
Pendapatan untuk Biocartis Group N.V. (BCART)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Biocartis Group N.V., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Biocartis Group N.V. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
$7.61B -
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
$4.76B -
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
- -
CN
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
$-252.70M -
US
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
$1.42B -
US